ADMA prelim FY2024 rev $417-425M, guides FY2025 >$485M

ADMA BIOLOGICS, INC.

2024-FY EPS reported $0.81 revenue$426,454,000

FY2024 preliminary total revenue $417-425M, exceeding prior guidance of $415M; cash >$100M with $30M debt repaid in Q4.
FY2025 revenue guided >$485M, net income >$170M, Adj EBITDA >$220M; FY2026 revenue >$600M, net income >$230M.
PAS submitted to FDA for yield enhancement process that could increase IG yields ~20%; approval expected mid-2025.
Executed long-term high titer plasma supply contracts from ~250 collection centers (5x increase) to support ASCENIV growth.
Balance sheet: net cash surplus vs. $75M debt; expect >$1B annual revenue before 2030 with outsized earnings growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.